Eli Lilly and Company $LLY Shares Sold by Vestcor Inc

Vestcor Inc lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 18.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 23,446 shares of the company’s stock after selling 5,282 shares during the quarter. Eli Lilly and Company makes up about 0.7% of Vestcor Inc’s portfolio, making the stock its 21st biggest holding. Vestcor Inc’s holdings in Eli Lilly and Company were worth $25,197,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Lowe Brockenbrough & Co. Inc. grew its stake in shares of Eli Lilly and Company by 26.0% in the 4th quarter. Lowe Brockenbrough & Co. Inc. now owns 8,469 shares of the company’s stock worth $9,101,000 after purchasing an additional 1,749 shares during the last quarter. MCF Advisors LLC grew its stake in shares of Eli Lilly and Company by 10.8% in the 4th quarter. MCF Advisors LLC now owns 2,765 shares of the company’s stock worth $2,971,000 after purchasing an additional 270 shares during the last quarter. Closed End Fund Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $430,000. First Command Advisory Services Inc. boosted its position in shares of Eli Lilly and Company by 68.7% in the 4th quarter. First Command Advisory Services Inc. now owns 2,335 shares of the company’s stock valued at $2,509,000 after purchasing an additional 951 shares during the period. Finally, Invst LLC boosted its position in shares of Eli Lilly and Company by 103.7% in the 4th quarter. Invst LLC now owns 6,864 shares of the company’s stock valued at $7,377,000 after purchasing an additional 3,494 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.7%

Shares of Eli Lilly and Company stock opened at $1,133.15 on Friday. The stock has a 50-day moving average price of $974.59 and a 200 day moving average price of $1,013.04. The company has a market cap of $1.07 trillion, a P/E ratio of 40.25, a P/E/G ratio of 1.23 and a beta of 0.53. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,166.29.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period in the prior year, the firm posted $3.34 EPS. The business’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark reversed its earlier exclusion and will now cover Eli Lilly’s Zepbound, a meaningful reimbursement win that could expand patient access and bolster obesity-drug sales. Article Title
• Positive Sentiment: WeightWatchers Med+ is now available through LillyDirect, reinforcing Lilly’s distribution ecosystem and strengthening its leadership in chronic weight management. Article Title
• Positive Sentiment: Lilly announced a new Phase 2b obesity trial for macupatide–eloralintide, adding another potential growth driver to its weight-loss pipeline beyond current GLP-1 products. Article Title
• Positive Sentiment: Jim Cramer highlighted Lilly as a potential winner against competitors, with attention on its new pill version of its weight-loss drug and broader competitive advantages. Article Title
• Positive Sentiment: Analysts and market commentary continue to frame LLY as a long-term winner, citing strong execution, deal-making, and diversification efforts beyond obesity drugs. Article Title
• Neutral Sentiment: Lilly also received coverage around its Phase 3 Libretto-432 cancer study and a $1.9 billion Ascidian partnership, both of which support the pipeline but are longer-term in nature. Article Title
• Neutral Sentiment: Broader health-care sector commentary and stock-screen articles were generally supportive, but they are less likely to be a direct driver of LLY’s move than the CVS and pipeline news. Article Title

Wall Street Analyst Weigh In

A number of research firms recently weighed in on LLY. Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Truist Financial reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Leerink Partners set a $1,119.00 price target on Eli Lilly and Company in a research report on Tuesday, May 26th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 6th. Finally, Argus increased their price objective on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,227.00.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.